Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648489 | 0.83 | TDP1 (0.57) | TDP1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL4626053 | 0.82 | TDP1 (0.59) | TDP1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL9933904 | 0.82 | TDP1 (0.59) | TDP1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL11914467 | 0.82 | TDP1 (0.59) | TDP1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL38655186 | 0.81 | TDP1 (0.54) | TDP1ALDH1A1KMT2ANPSR1 | |
| SCHEMBL16165623 | 0.81 | TDP1 (0.43) | TDP1CASP3LMNAPDE4APDE4B | |
| SCHEMBL16661414 | 0.81 | TDP1 (0.57) | TDP1CASP3LMNAPDE4APDE4B | |
| SCHEMBL29459229 | 0.80 | TDP1 (0.65) | TDP1CASP3LMNAPDE4APDE4B | |
| SCHEMBL6127956 | 0.80 | TDP1 (0.65) | TDP1CASP3LMNAPDE4APDE4B | |
| SCHEMBL27755640 | 0.80 | TDP1 (0.65) | TDP1CASP3LMNAPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646445-B1 | OXAZOLO[5,4-B]PYRIDIN-5-YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2646445-B1 | OXAZOLO[5,4-B]PYRIDIN-5-YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2646445-A1 | OXAZOLO [5, 4 -B]PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Eli Lilly and Company (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8288548-B2 | Oxazolo[5-4-b]pyridin-5-yl compounds | ELI LILLY AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288548-B2 | Oxazolo[5-4-b]pyridin-5-yl compounds | ELI LILLY AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288548-B2 | Oxazolo[5-4-b]pyridin-5-yl compounds | ELI LILLY AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120142724-A1 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142724-A1 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142724-A1 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012074761-A1 | OXAZOLO [5, 4 -B] PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074761-A1 | OXAZOLO [5, 4 -B] PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142724-A1 | OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS | CDK4, AURKB, PNPO | TDP1 1801/4885CASP3 105/4885LMNA 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.